Johnson & Johnson (JNJ) - Bull Of The Day
By Zacks Investment Research on July 15, 2009 | More Posts By Zacks Investment Research | Author's Website
Johnson & Johnson (JNJ) has an enormously diverse revenue stream consisting of market leading products in all three of its business segments. However, due to a number of products expected to experience declining sales as well as the affects of foreign exchange, revenue will fall in 2009.
We expect EPS to experience a more moderate decline, benefiting from improving margins and share buybacks. However, J&J’s consistency, product diversity, financial stability and long-term growth potential make it a very attractive holding in this turbulent market. We rate the stock a Buy based on the stock’s attractive valuation and strong company fundamentals. Our price target is $70.
If you like this article please...
Leave A Comment :
Recent Market Opinions:
Societe Generale Tells Investors How To Prepare For Potential “Global Collapse”
Month To Date Review Of The Market
Stock Picks For Monday: Nanometrics, Melco Crown Entertainment, MetroPCS Communications And Cell Therapeutics
Has Gold Just Broken Out Of Its Trend Channel?
One Reason Why The US Dollar Might Rise
Recent News:
Bay Street Stocks Slip Slightly Again - Canadian Commentary - 1 day ago
Stocks Close Mostly Lower Amid Disappointing Quarterly Results - U.S. Commentary - 1 day ago
Bay Street Stocks Linger Slightly Below Unchanged Level - Canadian Commentary - 2 days ago
Stocks Remain Stuck In The Red In Mid-Afternoon Trading - U.S Commentary - 2 days ago
European Markets Fall, Led By Banks, Oils - European Commentary - 2 days ago
Opinions From Our Contributors


